Skin-Homing Interleukin-4 and -13-Producing Cells Contribute to Bullous Pemphigoid: Remission of Disease is Associated with Increased Frequency of Interleukin-10-Producing Cells-Reference-Cited by-同舟云学术

Skin-Homing Interleukin-4 and -13-Producing Cells Contribute to Bullous Pemphigoid: Remission of Disease is Associated with Increased Frequency of Interleukin-10-Producing Cells

Published:2001-11 Issue:5 Volume:117 Page:1097-1102
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Teraki Yuichi,Hotta Takayuki,Shiohara Tetsuo

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference38 articles.

1. Functional diversity of helper T lymphocytes;Abbas;Nature,1996

2. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationship with disease intensity;Ameglio;Br J Dermatol,1998

3. Serum IgE levels in patients with bullous pemphigoid and its correlation to activity of the disease and anti-basement membrane zone antibodies;Asbrink;Acta Derm Venereol,1984

4. IL-10: evolving concepts;Borish;J Allergy Clin Immunol,1998

5. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO– and CD45RO+ subsets;Brinkmann;J Immunol,1995

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Dupilumab in Patients With Bullous Pemphigoid;JAMA Dermatology;2023-09-01

2. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches;Frontiers in Medicine;2023-08-08

3. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study;Frontiers in Immunology;2023-07-20

4. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment;British Journal of Dermatology;2023-05-04

5. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid;Annals of Medicine;2023-03-31